Haemoctin

Haemoctin is a prescription solution for injection containing human coagulation factor VIII, supplied as a sterile intravenous preparation. It is used to replace deficient factor VIII in patients with hemophilia A or acquired factor VIII deficiency. The product is manufactured in the European Union and is classified as a coagulation factor drug. It is indicated for both prophylactic and on‑demand therapy and is administered under medical supervision.

Haemoctin is indicated for the management of bleeding disorders related to factor VIII deficiency.

- Treatment of bleeding episodes in patients with congenital hemophilia A. - Routine prophylaxis to prevent spontaneous joint and muscle bleeds in hemophilia A. - Management of peri‑operative hemostasis for surgical procedures in hemophilia A patients. - Control of bleeding in acquired hemophilia A associated with autoantibodies. - Adjunct therapy for patients undergoing invasive dental or minor surgical interventions.

The safety profile of Haemoctin reflects the typical reactions observed with factor VIII replacement products.

Common: - Mild headache or fatigue. - Low‑grade fever. - Localized injection site erythema or swelling. - Transient increase in liver enzymes. - Nausea or mild abdominal discomfort.

Serious: - Development of inhibitors (neutralizing antibodies) to factor VIII. - Anaphylactic or severe allergic reactions. - Thromboembolic events, including deep‑vein thrombosis. - Disseminated intravascular coagulation (rare). - Severe hemolysis or renal impairment.

Clinicians should consider several precautions when prescribing Haemoctin.

- Assess for a history of inhibitors to factor VIII before initiating therapy. - Monitor for signs of allergic reaction, especially during the first infusion. - Use caution in patients with a history of thrombotic events or cardiovascular disease. - Evaluate liver and renal function periodically during long‑term treatment. - Avoid concurrent use with other pro‑coagulant agents unless medically justified. - Educate patients on proper storage and handling of the injectable solution.

Potential drug interactions with Haemoctin should be reviewed before treatment.

Avoid: - Concurrent administration of high‑dose activated pro‑thrombin complex concentrates, which may increase thrombotic risk. - Use of antifibrinolytic agents (e.g., tranexamic acid) without medical supervision in patients with known inhibitors.

Use with caution: - Immunosuppressive therapies that could affect inhibitor development. - Concomitant use of other clotting factor concentrates. - Medications that alter hepatic metabolism, such as certain antivirals. - Vaccines administered intramuscularly, which may increase bleeding risk at the injection site.